Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Web – sheet or filament bases; compositions of bandages; or...
Reexamination Certificate
2000-04-17
2001-08-28
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Web, sheet or filament bases; compositions of bandages; or...
C424S447000, C514S282000
Reexamination Certificate
active
06280766
ABSTRACT:
The invention relates to a method of treating patients with transdermal therapeutic systems containing active substance, said method ensuring the constant dosage over a prolonged period, especially for the treatment of patients with narcotics or drug dependency or patients suffering with painful conditions.
WO 93/19226 relates to a drug delivery system useful in treating an individual for a drug dependency. The drug delivery system, which may be a transdermal patch, is capable of delivering active substances, preferred lobeline, to an individual in a controlled, sustained release manner and providing long-term therapeutic levels of active substances to the individual. The transdermal patch is applied for the time of at least one day, preferably seven days and is removed before applying a new one.
EP-A1-0 432 945 discloses a transdermal delivery system for the treatment of cocaine and heroin addiction in a human or animal subject, which includes as the active ingredient buprenorphine. The transdermal delivery system is capable to deliver and maintain blood levels of from about 0.1 milligram to about 0.6 milligram.
WO 91/19474 relates to a method of making an laminated composite for administering buprenorphine transdermally to treat pain.
DE-A1-196 42 043 is directed to a transdermal therapeutic system for the delivery of active substances for the treatment of drug addicts. A preferred agent for this treatment is burpenorphin.
U.S. Pat. No. 5,362,496 discloses a method for treating conditions responsive to nicotine therapy, which utilizes transdermal nicotine delivery for obtaining base-line nicotine plasma levels. A transdermal patch containing a high load of nicotine is first administered for a period of several weeks and is then replaced by a transdermal patch containing a lower loading of nicotine.
U.S. Pat. No. 5,968,547 pertains to a method of treating pain or opioid addiction in patients by utilizing a transdermal delivery system containing buprenorphin. The method comprises transdermal delivery of buprenorphine at first at a high release rate and subsequently at a lower release rate either with the same delivery system or upon removal of the system and replacement with a different transdermal system.
U.S. Pat. No. 5,026,556 discloses a composition for transdermal delivery of buprenorphine.
REFERENCES:
patent: 5026556 (1991-06-01), Drust et al.
patent: 5362496 (1994-11-01), Baker et al.
patent: 5968547 (1999-10-01), Reder et al.
patent: 6143320 (2000-11-01), Becher et al.
patent: 9642043 (1996-10-01), None
patent: 0432945 (1990-11-01), None
patent: 0581057 (1993-07-01), None
patent: 9119474 (1991-12-01), None
patent: 9219226 (1992-11-01), None
patent: 9836728 (1998-08-01), None
Becher Frank
Wessling Werner
Ghali Isis
Klaniecki James E.
LTS Lehman Therapie-Systeme GmbH
Page Thurman K.
Speckman Ann W.
LandOfFree
Method for transdermal application of active substances at... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for transdermal application of active substances at..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for transdermal application of active substances at... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2535859